Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (67)

I-01Robert Leary

QRPEM, A Quasi-Random Parametric EM Method

Wednesday 10:15-11:45

I-02Donghwan Lee

Quantitative Analysis of Reflux Episodes in Gastroesophageal Reflux Disease (GERD)

Wednesday 10:15-11:45

I-03Eun-Kyung Lee

Various validation methods to check the estimation methods with stochastic sampling approach

Wednesday 10:15-11:45

I-04Joomi Lee

Population Pharmacokinetics of Sumatriptan in Healthy Korean Male Subjects

Wednesday 10:15-11:45

I-05Annabelle Lemenuel Diot

Identification of a dual mechanism of action (MoA) for Danoprevir (DNV), a protease inhibitor currently in phase 2, using a mechanistic viral kinetic model

Wednesday 10:15-11:45

I-06Sergei Leonov

Optimal design of population pharmacokinetic/pharmacodynamic studies

Wednesday 10:15-11:45

I-07

Clinical trial simulations of the anticancer agents- abiraterone and nilotinib

Wednesday 10:15-11:45

I-08

Clinical Trial Design Optimization: A Pharmacokinetic Sampling Plan for a Phase 3 Clinical Trial in Mild Alzheimer Disease Patients

Wednesday 10:15-11:45

I-09Floriane Lignet

Computational Model of In Vitro Breast Cancer Cells Spheroid-Formation

Wednesday 10:15-11:45

I-10Lars Lindbom

Addressing variability and uncertainty in pooled pre-clinical data improved the quality of compound selection of a gamma secretase modulator in Alzheimer’s Disease

Wednesday 10:15-11:45

I-11Rocio Lledo

Dose escalation studies for mAb: prior distributions selection and software comparison

Wednesday 10:15-11:45

I-13Gaohua Lu

Application of the Simcyp PBPK/PD model to Simulate PK and PD of Nifedipine in Japanese Populations

Wednesday 10:15-11:45

I-14

Refining the mechanism of CETP mediated lipid transfer in a stochastic model of lipoprotein metabolism and kinetics (LMK model)

Wednesday 10:15-11:45

I-15Peiming Ma

Organization of Target-Mediated Disposition (TMD) Models including Michaelis-Menten (MM), rapid-binding (RB), and quasi-steady-state (Qss) models

Wednesday 10:15-11:45

I-16Arianna Madrid Aispuro

A Systematic Approach to PKPD Model Development to describe Sleep Effects of Compounds with Different Mechanisms of Action Using Semi-Mechanistic Markov Chain Models

Wednesday 10:15-11:45

I-17Victor Mangas-Sanjuan

Three Compartment Model To Describe Atipical Permeability Profiles In CACO-2 Cells

Wednesday 10:15-11:45

I-18Mathilde Marchand

How to support a definitive bioequivalence study design using modeling and simulation

Wednesday 10:15-11:45

I-19John Maringwa

Model-based meta-analysis of summary clinical outcome data in idiopathic pulmonary fibrosis (IPF)

Wednesday 10:15-11:45

I-20Eleonora Marostica

Second order Markov modelling of HAMD responses in depression trials

Wednesday 10:15-11:45

I-21Amelie Marsot

Thiopental and esomeprazole in critically ill patients: Drug interaction.

Wednesday 10:15-11:45

I-22Silvia Illamola

Population pharmacokinetics of amikacin in newborns

Wednesday 10:15-11:45

I-23Maria Matoses Osborne

Development of a PBPK model for the anticancer drug Vivia009 and its main metabolite administered as a new delivery system in the Rat

Wednesday 10:15-11:45

I-24Veronese Mattia

Optimal Experimental Design for receptor drug development with PET studies

Wednesday 10:15-11:45

I-25Christophe Meille

Modified model of drug induced thrombocytopenia efficiently projects safe starting dose in human from preclinical data

Wednesday 10:15-11:45

I-26Sven Mensing

Evaluation of the long-term decline of platelets following Navitoclax (ABT-263) administration in Cancer Patients with a semi-physiological pharmacodynamic model

Wednesday 10:15-11:45

I-27François Mercier

A discussion on two approaches for indirect treatment comparisons based on public-domain metadata: The case of side-effects incidence

Wednesday 10:15-11:45

I-28Enrica Mezzalana

A Target-Mediated Drug Disposition model to quantify the relationship between Anti-CD3 monoclonal antibody and CD3/TCR receptors in Patients with autoimmune diseases.

Wednesday 10:15-11:45

I-29Jonathan Mochel

Using nonlinear mixed effects modeling to characterize the pharmacokinetics and pharmacodynamics of benazepril in dogs.

Wednesday 10:15-11:45

I-30Samer Mouksassi

Equivalence of locally acting drugs based on pharmacodynamic data: development of a novel 1 step method and use of trial simulations to assess sources of variability and power definitive studies

Wednesday 10:15-11:45

I-31Ricardo Nalda-Molina

Stochastic Simulations Assist to Improve a Poorly Designed Clinical Study for the CSF Pharmacokinetics of Doripenem

Wednesday 10:15-11:45

I-32Carmen Navarro

Computer simulations of bioequivalence trials: drugs with sequential metabolism

Wednesday 10:15-11:45

I-33Michael Neely

Non-Parametric Bayesian Fitting: A Novel Approach to Population Pharmacokinetic Modeling

Wednesday 10:15-11:45

I-34Thu Thuy Nguyen

Modelling the impact of fecal ciprofloxacin concentrations on fecal counts of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: towards new means to control the spread of resistance?

Wednesday 10:15-11:45

I-35Ronald Niebecker

Modelling of Anti-Drug Antibodies Directed Against a Monoclonal Antibody

Wednesday 10:15-11:45

I-36

The use of physiologically-based pharmacokinetic modeling in the design of pH-dependent target binding antibodies

Wednesday 10:15-11:45

I-37Elisabet Nielsen

Target Attainment Analysis to Evaluate Dosing Regimens of an Oral β-Lactam Antibioic

Wednesday 10:15-11:45

I-38Valerie Nock

Comparison of three PK/PD models for glycated haemoglobin in diabetes type 2 patients treated with lixisenatide

Wednesday 10:15-11:45

I-39Yookhwan Noh

Bioequivalence evaluation using population modeling method

Wednesday 10:15-11:45

I-40Joakim Nyberg

The robustness of global optimal designs

Wednesday 10:15-11:45

I-41Kayode Ogungbenro

A semi-mechanistic gastric emptying model for double peaks in pharmacokinetics using LDOPA data

Wednesday 10:15-11:45

I-42

The Pharmacokinetic Profile of Intravenous Paracetamol in Adult Patients Undergoing Major Surgery: A Population Analysis

Wednesday 10:15-11:45

I-43Sung Min Park

Population pharmacokinetics of S-amlodipine in healthy Korean male subjects

Wednesday 10:15-11:45

I-45Zinnia Parra-Guillen

Tumour Growth Modelling In Immunotherapy

Wednesday 10:15-11:45

I-46

Modeling of the effect of G-CSF in limiting the neutropenic toxicity of carboplatin

Wednesday 10:15-11:45

I-47

Prediction of serum and cerebrospinal fluid concentrations of carbamazepine: An application of parameter estimation and the permeability limited 4-compartment brain model in Simcyp®

Wednesday 10:15-11:45

I-48Kirill Peskov

Mechanistic modeling approach relating human gut microbial community to physiologically-relevant biomarkers

Wednesday 10:15-11:45

I-49Klas Petersson

Simultaneous modeling of prolactin data following administration of seven D2–receptor antagonists in rats; Model-based in vitro – rat – human scaling

Wednesday 10:15-11:45

I-50Chiara Piana

Non-adherence to antiretroviral combination therapy in HIV-infected children

Wednesday 10:15-11:45

I-51

Mathematical Model of Homeostasis of Endogenous Hormones Following Hormone Replacement Therapy

Wednesday 10:15-11:45

I-52Venkatesh Pilla Reddy

Translational PKPD modeling in schizophrenia: linking receptor occupancy of antipsychotics to efficacy and safety

Wednesday 10:15-11:45

I-53Elodie Plan

Bayesian Joint Modeling of Bone Mineral Density and Repeated Time-To-Fracture Event for Multiscale Bone Systems Model Extension

Wednesday 10:15-11:45

I-54Bart Ploeger

Investigation of a Data Transformation Procedure to Improve Identifiability of Efficacy and Potency: Application to Continuous Elevated Plus-Maze Data in Rats

Wednesday 10:15-11:45

I-55Arnaud Quelin

How Anti-cancer Targeted Therapies Used in Combination Interact? Analysis with a Semi-mechanistic Model of Minimal Signalling Networks

Wednesday 10:15-11:45

I-56Christian Hove Claussen

Pharmacokinetics of concentrated insulin mixtures: a biosimulation approach

Wednesday 10:15-11:45

I-57Dinko Rekic

External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1 infected patients

Wednesday 10:15-11:45

I-58Sylvie Retout

Prediction of occurrence of thrombocytopenia to select Phase 1b dose and dosing regimen for a selective inhibitor of p53-MDM2 in patients with solid tumors

Wednesday 10:15-11:45

I-59Benjamin Ribba

A model for low-grade glioma tumor growth and response to chemotherapy and radiotherapy

Wednesday 10:15-11:45

I-60Nikita Rodichenko

Multimodal Physiologically-Based Modelling and Analysis of Kinetics of Drug-Delivery with Modular Nanotransporters (MNT)

Wednesday 10:15-11:45

I-61Rikke Meldgaard Røge

Integrated model of glucose homeostasis including the effect of exogenous insulin

Wednesday 10:15-11:45

I-62Hyerang Roh

Quantitative assessment of drug response in male patients with severe nocturia receiving a combined medication of solifenacin and tamsulosin

Wednesday 10:15-11:45

I-63Rachel Rose

Prediction of the Hypnotic Effects of Zolpidem by Extrapolation of a Mechanism-Based PKPD Model Developed for Triazolam in Healthy Volunteers.

Wednesday 10:15-11:45

I-64

Pharmacokinetic/Pharmacodynamic Simulations Of The vWF Targeting Nanobody® ALX-0081 In Pediatric Patients With TTP

Wednesday 10:15-11:45

I-65Amit Roy

Characterization of the Occurrence, Severity, and Duration of Immune-Related Adverse Events (irAEs) in Advanced Melanoma Patients Treated with Ipilimumab

Wednesday 10:15-11:45

I-66Hauke Ruehs

Integrated PK/PD model for oxaliplatin in different human matrices

Wednesday 10:15-11:45

I-67Alberto Russu

A new, second-order indirect model of depression time course

Wednesday 10:15-11:45

I-68Vargo Ryan

Comparator based dose-response model prediction of clinical irrelevance following near miss bioequivalence results for Cmax

Wednesday 10:15-11:45

I-69Yu-Yuan Chiu

Dose-Response Model of Lurasidone Treatment in Schizophrenia

Wednesday 10:15-11:45